William Blair Analysts Decrease Earnings Estimates for TARS

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - William Blair cut their Q2 2025 EPS estimates for Tarsus Pharmaceuticals in a research note issued to investors on Monday, July 14th. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings of ($0.48) per share for the quarter, down from their previous forecast of ($0.43). The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($3.17) per share. William Blair also issued estimates for Tarsus Pharmaceuticals' FY2025 earnings at ($1.43) EPS.

Other research analysts also recently issued reports about the company. HC Wainwright raised Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price objective on the stock in a research note on Tuesday, May 27th. Oppenheimer assumed coverage on Tarsus Pharmaceuticals in a research report on Monday, June 2nd. They issued an "outperform" rating and a $75.00 target price for the company. Wall Street Zen cut Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. The Goldman Sachs Group increased their price target on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research report on Monday, May 5th. Finally, Guggenheim lifted their price target on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $66.67.

Tarsus Pharmaceuticals Stock Up 4.5%

NASDAQ TARS traded up $1.85 during trading on Wednesday, reaching $43.25. 1,255,389 shares of the company's stock were exchanged, compared to its average volume of 687,244. The firm has a market capitalization of $1.82 billion, a PE ratio of -15.84 and a beta of 0.80. The company has a current ratio of 5.57, a quick ratio of 5.54 and a debt-to-equity ratio of 0.21. The company's fifty day simple moving average is $41.85 and its 200-day simple moving average is $46.62. Tarsus Pharmaceuticals has a fifty-two week low of $20.08 and a fifty-two week high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 44.91% and a negative return on equity of 39.72%. The company had revenue of $78.34 million during the quarter, compared to analyst estimates of $72.50 million.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of large investors have recently modified their holdings of TARS. Crowley Wealth Management Inc. bought a new position in Tarsus Pharmaceuticals during the fourth quarter worth about $25,000. GF Fund Management CO. LTD. acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $44,000. Amalgamated Bank increased its holdings in shares of Tarsus Pharmaceuticals by 30.1% during the 1st quarter. Amalgamated Bank now owns 1,274 shares of the company's stock worth $65,000 after acquiring an additional 295 shares during the last quarter. Quarry LP bought a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at $166,000. Finally, AlphaQuest LLC acquired a new stake in Tarsus Pharmaceuticals during the 1st quarter valued at $189,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.